2026 ICD-10-CM Diagnosis Code Z15.07Genetic susceptibility to malignant neoplasm of urinary tract
Z15.07 is a billable ICD-10-CM diagnosis code for genetic susceptibility to malignant neoplasm of urinary tract. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for Z15.07.
Present on Admission (POA)Billing
Z15.07 is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
- Genetic
- susceptibility to disease NEC - Z15.89
- urinary tract - Z15.07
External Cause of Injuries IndexGuidance
References for this code in the External Cause of Injuries Index.
- Genetic
- susceptibility to disease NEC
- malignant neoplasm
- urinary tract
Code History & ChangesHistory
New Code Z15.07 was added to the ICD-10-CM code set for FY 2026, effective October 1, 2025.
Replacement Z15.07 replaces the following previously assigned code(s):
- Z15.09 - Genetic susceptibility to other malignant neoplasm
Questions About Z15.07Overview
Is Z15.07 (Genetic susceptibility to malignant neoplasm) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report genetic susceptibility to malignant neoplasm of urinary tract on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
Can Z15.07 be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because genetic susceptibility to malignant neoplasm of urinary tract describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
Is Z15.07 exempt from POA reporting?
Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for genetic susceptibility to malignant neoplasm of urinary tract on inpatient claims.
